Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Más filtros

Bases de datos
Tipo del documento
País de afiliación
Intervalo de año de publicación
1.
Curr Vasc Pharmacol ; 18(6): 580-591, 2020.
Artículo en Inglés | MEDLINE | ID: mdl-32268865

RESUMEN

Juvenile idiopathic arthritis (JIA), is a term used to describe a group of inflammatory disorders beginning before the age of 16 years. Although for the majority of children remission is achieved early, those with systemic or polyarticular form of the disease may present persistent symptoms in adulthood. Considering that there is overlap in the pathogenesis of JIA with adult rheumatic diseases, concerns have been raised as to whether JIA patients could be at increased cardiovascular (CV) risk in the long-term. In this review, we summarize evidence for CV involvement in JIA and present data on CV risk factors and surrogate markers of arterial disease. We also provide information on beneficial and harmful CV effects of anti-inflammatory medications in the context of JIA and suggest strategies for CV screening. Overall, patients with systemic forms of JIA demonstrate an adverse lipid profile and early arterial changes relevant to accelerated arterial disease progression. Although there is paucity of data on CV outcomes, we recommend a holistic approach in the management of JIA patients, which includes CV risk factor monitoring and lifestyle modification as well as use, when necessary, of antiinflammatory therapies with documented CV safety.


Asunto(s)
Artritis Juvenil/epidemiología , Enfermedades Cardiovasculares/epidemiología , Inflamación/epidemiología , Adolescente , Adulto , Edad de Inicio , Animales , Antiinflamatorios/efectos adversos , Antirreumáticos/efectos adversos , Artritis Juvenil/tratamiento farmacológico , Artritis Juvenil/inmunología , Enfermedades Cardiovasculares/inmunología , Enfermedades Cardiovasculares/prevención & control , Niño , Preescolar , Femenino , Factores de Riesgo de Enfermedad Cardiaca , Humanos , Inflamación/tratamiento farmacológico , Inflamación/inmunología , Masculino , Pronóstico , Medición de Riesgo , Adulto Joven
2.
Am J Clin Dermatol ; 5(4): 211-6, 2004.
Artículo en Inglés | MEDLINE | ID: mdl-15301568

RESUMEN

Acne vulgaris is a common dermatosis affecting 80% of the population. To date, different treatments have been used to manage this condition. Antibacterials and retinoids are currently the mainstay of treatment for acne, but their success rate varies. Phototherapy is emerging as an alternative option to treat acne vulgaris. Studies examining the role of different wavelengths and methods of light treatment have shown that phototherapy with visible light, specifically blue light, has a marked effect on inflammatory acne lesions and seems sufficient for the treatment of acne. In addition, the combination of blue-red light radiation seems to be superior to blue light alone, with minimal adverse effects. Photodynamic therapy has also been used, even in nodular and cystic acne, and had excellent therapeutic outcomes, although with significant adverse effects. Recently, low energy pulsed dye laser therapy has been used, and seems to be a promising alternative that would allow the simultaneous treatment of active acne and acne scarring. Further studies are needed to clarify the role of phototherapy as a monotherapy or an adjuvant treatment in the current management of acne vulgaris.


Asunto(s)
Acné Vulgar/terapia , Fototerapia/métodos , Humanos , Luz , Rayos Ultravioleta
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA